ring finger protein 126 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored RNF126P1 profile across patient tissues and cancer cell-line models. RNF126P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNF126P1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, RNF126P1 RNA expression shows 12,288 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where RNF126P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF126P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF126P1 survival associations across molecular data types. RNF126P1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF126P1 RNA expression–survival associations across cancer types. High RNF126P1 expression shows unfavorable associations in LGG and ESCA, but favorable associations in MESO, HNSC, LUAD and ACC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for RNF126P1 RNA expression.
This table summarizes RNF126P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNF126P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF126P1 shows lower tumor expression in KIRC, THCA, LUSC, KICH and PRAD and higher tumor expression in LIHC. The KIRC box plot shows higher RNF126P1 RNA expression in normal versus tumor tissue (log2 FC = −0.357, t-test p < 0.001).
This table shows molecular features associated with RNF126P1 in patient tissues and cancer cell lines. In patient samples, RNF126P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF126P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
